Jump to ContentJump to Main Navigation
Show Summary Details
In This Section

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982

Online
ISSN
1437-4331
See all formats and pricing
In This Section
Volume 53, Issue 1 (Jan 2015)

Issues

Serum fucosylated haptoglobin in chronic liver diseases as a potential biomarker of hepatocellular carcinoma development

Hitomi Asazawa
  • Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Osaka, Japan
/ Yoshihiro Kamada
  • Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Osaka, Japan
/ Yuri Takeda
  • Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Osaka, Japan
/ Shinji Takamatsu
  • Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Osaka, Japan
/ Shinichiro Shinzaki
  • Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Osaka, Japan
/ Youkoku Kim
  • Department of Surgery, Osaka Rosai Hospital, Osaka, Japan
/ Riichiro Nezu
  • Department of Surgery, Osaka Rosai Hospital, Osaka, Japan
/ Noriyoshi Kuzushita
  • Department of Hepato-Gastroenterology, Osaka National Hospital, Osaka, Japan
/ Eiji Mita
  • Department of Hepato-Gastroenterology, Osaka National Hospital, Osaka, Japan
/ Michio Kato
  • Department of Hepato-Gastroenterology, Osaka National Hospital, Osaka, Japan
/ Eiji Miyoshi
  • Corresponding author
  • Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Osaka, Japan
  • Email:
Published Online: 2014-07-23 | DOI: https://doi.org/10.1515/cclm-2014-0427

Abstract

Background: Fucosylation is one of the most important glycosylation events involved in cancer and inflammation. We previously developed a lectin antibody ELISA kit to measure fucosylated haptoglobin (Fuc-Hpt), which we identified as a novel cancer biomarker. In this study, we investigated Fuc-Hpt as a biomarker in chronic liver diseases, especially in hepatocellular carcinoma (HCC).

Methods: We measured serum Fuc-Hpt levels using our ELISA kit in 318 patients with chronic liver diseases, including 145 chronic hepatitis (CH) patients, 81 liver cirrhosis (LC) patients, and 92 HCC patients. During a long-term follow-up period of 7 years (1996–2003), Fuc-Hpt levels were measured at three different time points in 19 HCC patients. Serum Fuc-Hpt levels were also examined with a short-term follow-up period of 3 years (2009–2012) in 13 HCC patients.

Results: Fuc-Hpt levels increased with liver disease progression. Patients with LC and HCC showed significantly increased Fuc-Hpt levels in comparison to CH patients or healthy volunteers. Fuc-Hpt levels tended to be higher in HCC patients than in LC patients. Fuc-Hpt was better than α-fetoprotein (AFP) and AFP-L3 for predicting HCC [diagnosed by computed tomography (CT) or ultrasound] in LC patients with long-term follow-up. More than 80% of LC patients with long-term follow-up showed increased Fuc-Hpt during hepatocarcinogenesis, and 38% of early-stage HCC patients with short-term follow-up showed a gradual increase in Fuc-Hpt before imaging diagnosis.

Conclusions: These results suggest that Fuc-Hpt is a novel and potentially useful biomarker for predicting liver disease progression and HCC development.

This article offers supplementary material which is provided at the end of the article.

Keywords: α-fetoprotein (AFP); fucosylation; lectin antibody ELISA kit; protein induced by vitamin K antagonist II (PIVKA-II)

References

  • 1.

    Miyoshi E, Moriwaki K, Nakagawa T. Biological function of fucosylation in cancer biology. J Biochem 2008;143:725–9. [Web of Science]

  • 2.

    Wang M, Long RE, Comunale MA, Junaidi O, Marrero J, Di Bisceglie AM, et al. Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2009;18:1914–21. [Crossref] [Web of Science]

  • 3.

    Hashimoto S, Asao T, Takahashi J, Yagihashi Y, Nishimura T, Saniabadi AR, et al. alpha1-acid glycoprotein fucosylation as a marker of carcinoma progression and prognosis. Cancer 2004;101:2825–36.

  • 4.

    Debruyne EN, Vanderschaeghe D, Van Vlierberghe H, Vanhecke A, Callewaert N, Delanghe JR. Diagnostic value of the hemopexin N-glycan profile in hepatocellular carcinoma patients. Clin Chem 2010;56:823–31. [Web of Science]

  • 5.

    Taketa K. Alpha-fetoprotein: reevaluation in hepatology. Hepatology 1990;12:1420–32. [PubMed] [Crossref]

  • 6.

    Breborowicz J, Mackiewicz A, Breborowicz D. Microheterogeneity of alpha-fetoprotein in patient serum as demonstrated by lectin affino-electrophoresis. Scand J Immunol 1981;14:15–20. [PubMed] [Crossref]

  • 7.

    Taketa K, Izumi M, Ichikawa E. Distinct molecular species of human alpha-fetoprotein due to differential affinities to lectins. Ann N Y Acad Sci 1983;417:61–8.

  • 8.

    Aoyagi Y. Carbohydrate-based measurements on alpha-fetoprotein in the early diagnosis of hepatocellular carcinoma. Glycoconj J 1995;12:194–9. [PubMed]

  • 9.

    Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009;137:110–8.

  • 10.

    Okuyama N, Ide Y, Nakano M, Nakagawa T, Yamanaka K, Moriwaki K, et al. Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer 2006;118:2803–8.

  • 11.

    Nakano M, Nakagawa T, Ito T, Kitada T, Hijioka T, Kasahara A, et al. Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers. Int J Cancer 2008;122:2301–9.

  • 12.

    Takeda Y, Shinzaki S, Okudo K, Moriwaki K, Murata K, Miyoshi E. Fucosylated haptoglobin is a novel type of cancer biomarker linked to the prognosis after an operation in colorectal cancer. Cancer 2012;118:3036–43.

  • 13.

    Narisada M, Kawamoto S, Kuwamoto K, Moriwaki K, Nakagawa T, Matsumoto H, et al. Identification of an inducible factor secreted by pancreatic cancer cell lines that stimulates the production of fucosylated haptoglobin in hepatoma cells. Biochem Biophys Res Commun 2008;377:792–6. [Web of Science]

  • 14.

    Matsumoto H, Shinzaki S, Narisada M, Kawamoto S, Kuwamoto K, Moriwaki K, et al. Clinical application of a lectin-antibody ELISA to measure fucosylated haptoglobin in sera of patients with pancreatic cancer. Clin Chem Lab Med 2010;48:505–12. [Web of Science]

  • 15.

    Kormoczi GF, Saemann MD, Buchta C, Peck-Radosavljevic M, Mayr WR, Schwartz DW, et al. Influence of clinical factors on the haemolysis marker haptoglobin. Eur J Clin Invest 2006;36: 202–9.

  • 16.

    Kamada Y, Kinoshita N, Tsuchiya Y, Kobayashi K, Fujii H, Terao N, et al. Reevaluation of a lectin antibody ELISA kit for measuring fucosylated haptoglobin in various conditions. Clin Chim Acta 2013;417:48–53. [Web of Science]

  • 17.

    Kagebayashi C, Yamaguchi I, Akinaga A, Kitano H, Yokoyama K, Satomura M, et al. Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis. Anal Biochem 2009;388:306–11. [Web of Science]

  • 18.

    Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289–93.

  • 19.

    Nakagawa T, Uozumi N, Nakano M, Mizuno-Horikawa Y, Okuyama N, Taguchi T, et al. Fucosylation of N-glycans regulates the secretion of hepatic glycoproteins into bile ducts. J Biol Chem 2006;281:29797–806.

  • 20.

    Nakagawa T, Takeishi S, Kameyama A, Yagi H, Yoshioka T, Moriwaki K, et al. Glycomic analyses of glycoproteins in bile and serum during rat hepatocarcinogenesis. J Proteome Res 2010;9:4888–96. [Web of Science] [Crossref]

About the article

Corresponding author: Eiji Miyoshi, MD, PhD, Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, 1-7, Yamada-oka, Suita, Osaka 565-0871, Japan, Phone/Fax: +81 6 68792590, E-mail:

aHitomi Asazawa and Yoshihiro Kamada contributed equally to this study.


Received: 2014-04-19

Accepted: 2014-06-30

Published Online: 2014-07-23

Published in Print: 2015-01-01



Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2014-0427. Export Citation

Supplementary Article Materials

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Abolfazl Pourhassan, Daniel Fadaei Fouladi, Simin Mirakhor Samani, and Sam Morshedi Asl
Biological Trace Element Research, 2015

Comments (0)

Please log in or register to comment.
Log in